NGL Fine Chem Ltd

About

Established in 1981, NGL Fine-Chem Limited manufacturers and markets APIs, Intermediates and Finished Dosage forms for human and animal pharmaceutical product. It caters to various Indian and global companies with high quality and reliable products. [1]

Key Points

Product Portfolio
Presently, Veterinary APIs is the main product of the company which account for 89% of its revenues, followed by Veterinary Formulations (5%), Human APIs (2%), Intermediates (2%) & Others (2%). [1] The company has been able to increase its market share in the lower share of its portfolio which has increased to the levels of 50-60%. [2]

See full details
  • Market Cap 1,579 Cr.
  • Current Price 2,554
  • High / Low 3,789 / 800
  • Stock P/E 23.7
  • Book Value 250
  • Dividend Yield 0.07 %
  • ROCE 53.5 %
  • ROE 44.8 %
  • Face Value 5.00

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company is expected to give good quarter

Cons

  • Stock is trading at 10.22 times its book value
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2018 Dec 2018 Mar 2019 Jun 2019 Sep 2019 Dec 2019 Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
39 34 43 41 37 37 35 42 68 73 72 76
32 27 33 32 33 34 33 29 48 50 51 52
Operating Profit 7 7 11 8 4 3 2 13 20 22 21 24
OPM % 18% 21% 25% 21% 12% 9% 6% 32% 30% 31% 29% 31%
Other Income 2 1 1 1 1 1 1 2 3 4 2 5
Interest 1 1 1 0 1 1 1 1 1 0 0 0
Depreciation 1 2 2 2 2 2 2 2 2 2 2 2
Profit before tax 7 6 10 7 3 2 0 13 21 23 21 26
Tax % 34% 30% 30% 30% 14% 34% 165% 27% 23% 24% 33% 25%
Net Profit 4 4 7 5 2 1 -0 9 16 18 14 19
EPS in Rs 7.15 6.59 11.02 8.42 3.80 1.83 -0.32 15.17 25.59 28.67 22.40 30.96

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 TTM
153 152 258 289
121 130 178 202
Operating Profit 32 22 80 87
OPM % 21% 14% 31% 30%
Other Income 4 1 8 13
Interest 3 3 2 2
Depreciation 6 8 8 8
Profit before tax 28 12 78 90
Tax % 27% 31% 27%
Net Profit 20 8 57 66
EPS in Rs 32.58 13.50 91.81 107.62
Dividend Payout % 5% 13% 2%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 89%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 426%
Stock Price CAGR
10 Years: 68%
5 Years: 51%
3 Years: 78%
1 Year: 181%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: 45%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021
3 3 3
Reserves 89 96 151
Borrowings 27 28 16
23 26 37
Total Liabilities 142 154 208
61 68 64
CWIP 0 0 12
Investments 9 11 29
73 75 102
Total Assets 142 154 208

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021
9 20 27
-10 -20 -25
0 -1 -1
Net Cash Flow -1 -0 2

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021
Debtor Days 79 63 53
Inventory Days 106 155 132
Days Payable 88 108 86
Cash Conversion Cycle 97 110 99
Working Capital Days 116 106 83
ROCE % 14% 54%

Shareholding Pattern

Numbers in percentages

Dec 2018 Mar 2019 Jun 2019 Sep 2019 Dec 2019 Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021
65.45 65.45 65.45 73.83 73.83 73.81 73.81 73.81 73.81 73.81 73.81 73.81
0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
34.55 34.55 34.55 26.17 26.16 26.19 26.19 26.19 26.19 26.19 26.19 26.19

Documents

Announcements